7MW 3711
Alternative Names: 7MW-3711Latest Information Update: 09 Sep 2024
At a glance
- Originator Mabwell (Shanghai) Bioscience
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Apoptosis stimulants; DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 09 Sep 2024 Phase-I clinical trials in Solid tumours (Late-stage disease) in USA (Parenteral), prior to September 2024 (Mabwell (Shanghai) Bioscience pipeline, September 2024)
- 16 Jul 2024 7MW 3711 receives Orphan Drug status for Small cell lung cancer in USA
- 20 Feb 2024 US FDA approves IND application for 7MW3711 in Solid tumors